Michael Thomas Henderson, Director at Spyre Therapeutics, Inc. (SYRE), sold 20,000 shares at $100.00 ($2.0M) on 2026-06-22, disclosed to the SEC on 2026-06-23.
Scheduled sale ($2.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |
| SYRE | SELL | 2026-05-08 | $6.0M | — | Filing → |